INFU 最新10-Q变化
将 INFU 最新的定期申报(10-K/10-Q)与上一份同类型申报逐章节对比:每个章节新增/删除的段落数与原文摘录。全部为确定性文本对比——无相似度评分、无方向判断、非投资建议。
对比:10-Q · 2026-08-04 与上一份 10-Q · 2026-05-08
| 章节 | 结果 | 新增 | 删除 | 微调 | 未变 |
|---|---|---|---|---|---|
| 管理层讨论与分析 | 文字有新增/删除 | +28 | −14 | ~12 | 23 |
| 市场风险(第3项) | 文字有新增/删除 | 0 | 0 | ~2 | 2 |
| 控制与程序 | 文字有新增/删除 | +4 | −3 | 0 | 1 |
| 法律诉讼 | 无段落级文字变化 | 0 | 0 | 0 | 1 |
| 其他信息 | 文字有新增/删除 | 0 | 0 | ~1 | 0 |
计数单位为段落;"新增/删除"指相对上一份文件新增/删除的文字,不含方向或好坏判断。
未列出(无法可靠提取或缺失):风险因素
代表性摘录
每个章节最多 5 条、每条约 300 字符的原文摘录,直接来自两份 SEC 文件。
管理层讨论与分析
相对上期新增的文字 · 来源:10-Q · 2026-08-04
Net revenues for the quarter ended June 30, 2026 (“second quarter of 2026”) were $36.9 million, an increase of $0.9 million, or 2.6%, compared to $36.0 million for the quarter ended June 30, 2025 (“second quarter of 2025”). The increase included higher net revenues for the Patient Services segment p…
Patient Services net revenue of $24.8 million increased $3.3 million, or 15.2%, during the second quarter of 2026 compared to the prior year period. This increase was primarily attributable to additional treatment volume and increased third-party payer collections in Oncology and Wound Care. The imp…
Compression Devices (PCDs) and Adjustable Compression Wraps (ACW’s) stemming from two new supplier relationships. There was no PCD or ACW revenue in the second quarter of 2025 because the new products launched during the third quarter of 2025, with the first manufacturer, and during the first quarte…
Gross profit for the second quarter of 2026 of $21.4 million increased by $1.5 million, or 7.7%, compared to the second quarter of 2025. This increase was due to the increase in net revenues and by a higher gross profit percentage of net revenue (“gross margin”). Gross margin was 58.0% during the se…
Patient Services gross profit was $15.3 million during the second quarter of 2026, representing an increase of $1.5 million, or 10.9%, compared to the prior year period. The increase reflected the higher net revenue offset partially by lower gross margin, which decreased from the prior year by 2.4% …
相对上期删除的文字 · 来源:10-Q · 2026-05-08
Net revenues for the three-month period ended March 31, 2026 (“three-month period of 2026”) were $33.7 million, a decrease of $1.0 million, or 3.0%, compared to $34.7 million for the three-month period ended March 31, 2025 (“three-month period of 2025”). The decrease included lower net revenues for …
Patient Services net revenue of $22.1 million increased $1.3 million, or 6.4%, during the three-month period of 2026 compared to the same prior year period. This increase was primarily attributable to additional treatment volume in Oncology
and Wound Care which were partially offset by a lower amount in Pain Management. The improved volume and collections benefited Oncology revenue by $0.4 million or 2.4%, and Wound Care treatment revenue by $1.1 million, or 116.0%. Pain Management revenue decreased by $0.2 million, or 15.1%. The Wound…
Gross profit of $19.7 million for the three-month period of 2026 increased $0.5 million, or 2.7%, from $19.2 million for the three-month period of 2025. This increase was due to the increase in gross margin partially offset by the lower net revenues. Gross margin increased to 58.4% during the three-…
Patient Services gross profit was $14.3 million during the three-month period of 2026, representing an increase of $1.1 million, or 8.6%, compared to the same prior year period. The improvement reflected increased net revenue and a higher gross margin, which increased from the prior year by 1.3% to …
控制与程序
相对上期新增的文字 · 来源:10-Q · 2026-08-04
We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material informa…
including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10…
During the six-month period ended June 30, 2026, the Company migrated certain of our business applications and financial processing systems to a newly implemented Enterprise Resource Planning (“ERP”) system. The migration and implementation impacted operational processes, as well as certain accounti…
Except with respect to the implementation of the ERP, there have been no changes in our internal control over financial reporting during the six-month period ended June 30, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reportin…
相对上期删除的文字 · 来源:10-Q · 2026-05-08
We maintain a set of disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material informa…
During the three-month period ended March 31, 2026, the Company migrated certain of our business applications and financial processing systems to a newly implemented Enterprise Resource Planning (ERP) system. The migration and implementation impacted operational processes, as well as certain account…
Except with respect to the implementation of the ERP system, there have been no changes in our internal control over financial reporting during the three-month period ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financia…
如何读 10-Q 的风险因素(第 1A 项)
10-Q 的风险因素章节有三种常见形态,本页按其一分类展示:
- 指向(pointer) — 公司仅声明"无重大变化"并指向年度 10-K 的完整风险因素;本季没有自己的风险文本可对比。
- 部分更新(partial) — 公司写明"除下述外无重大变化",只更新部分风险;摘录展示的正是本季新增的内容。
- 全文重述(restated) — 本季重新给出完整风险因素。若上一季只是"指向",则无法逐段对比,本页会将其标为"本季全文重述"。
这只是对文件结构的客观描述,不构成对风险高低的判断。
数据来自 SEC EDGAR 两份申报文件的文本级对比 · 确定性计算(无 AI 生成内容)· 仅供参考 · 非投资建议